Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01833169
Title BKM120 for Patients With PI3K-activated Tumors
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

hematologic cancer

Therapies

Buparlisib

Age Groups: senior | adult
Covered Countries USA

Additional content available in CKB BOOST